Furthermore, clinical studies have demonstrated that while continuous infusion of native GLP-1 in type 2 diabetic patients reduced blood glucose uniformly after 1 or 6 weeks of treatment [41], a comparison of 16-h and 24-h continuous infusion showed that a better glycemic control could obtained with sustained 24-h treatment [42]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.